Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/bcj.2014.1; published online 21 February 2014
Since the publication of this article, the authors have identified an error concerning one of the author affiliation addresses. KC Anderson was incorrectly affiliated to the following address: ‘Merck & Co. Inc., Whitehouse Station, NJ, USA’. The correct address details are shown here.
The article has also been rectified, and now carries the correct information.
The Authors would like to apologise for any inconvenience this may have caused.
The online version of the original article can be found at 10.1038/bcj.2014.1
About this article
Cite this article
Siegel, D., Richardson, P., Dimopoulos, M. et al. Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer Journal 4, e202 (2014) doi:10.1038/bcj.2014.23
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up
Biology of Blood and Marrow Transplantation (2019)
Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in multiple myeloma via epigenetic regulation of p21
Experimental Hematology (2018)
Blood Cancer Journal (2017)
Journal of Hematology & Oncology (2016)
The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies
Cancer Treatment Reviews (2016)